Evidence map›Paper›PMID 25550925›Full record

ArticleInternational journal of clinical and experimental medicine2014

Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1.

Wenjuan Liu, Di Wang, Kaibin Song, Li Chen, Yanmei Zhu, Peifang Liu, Yulan Zhu

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Polysaccharides from the Edible MushroomInternational journal of molecular sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenjuan LiuDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Di WangDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Kaibin SongDepartment of Head and Neck Surgery, The Third Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Li ChenDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Yanmei ZhuDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Peifang LiuDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Yulan ZhuDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University Harbin 150081, China.
Second Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inhibition of voltage-gated potassium channels (Kv) plays an important role in the cerebral hypoxia-induced cell death. The activity of Kv can be inhibited by 15-hydroxyeicosatetrienoic acid (15-HETE). Therefore, as the key enzyme which catalyzed the formation of 15-HETE, 15-LOX may be involved in Kv inhibition induced by cerebral hypoxia. In our study, Wistar rats cerebral arterial smooth muscle cells (CASMCs) were placed under the condition of hypoxia and control, 15-LOX was proved involved in hypoxia-induced vasoconstriction. Furthermore, 15-LOX gene over expression under normoxic condition, as well as 15-LOX gene knockout or inhibition under hypoxic condition was performed to investigate the expression and activity of Kv1.5 and Kv2.1 in CASMCs. Results showed that both hypoxia and 15-LOX over expression could cause Kv1.5 and Kv2.1 suppression, but no suppression was observed under hypoxic condition when 15-LOX gene was knockout or inhibited, which made 15-LOX a new target for the treatment of cerebral hypoxia. In conclusion, AA/15-LOX/15-HETE induces vasoconstriction by down-regulating Kv channels, and Kv2.1/1.5 channels are the targets. Our study also suggests a therapeutic strategy to improve ischemic vascular occlusion by lowering 15-HETE level and preventing Kv channel down-regulation, which makes 15-LOX as a new target for the treatment of cerebral hypoxia.

Indexed as

15-hydroxyeicosatetrienoic acid (15-HETE)15-lipoxygenase (15-LOX)hypoxiaKv1.5Kv2.1

Identifiers

PMID25550925
PMCPMC4276183
OpenAlexW2206154709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.